Medtronic saw 6.6% year over year growth in the second quarter of fiscal year 2026, according to financial results posted Nov. 18.
Five things to know:
1. Medtronic saw $9 billion in global revenue, and $4.5 billion in U.S. sales.
2. Neuroscience sales were $2.5 billion, a 4.5% increase year over year.
3. Cranial and spinal technologies saw 5.2% year over year growth with $1.3 billion. Specialty therapies and neuromodulation saw year-over-year growth of 0.9% and 8.3%, respectively.
4. Medical Surgical business was $2.2 billion, a 2.1% increase year over year, and cardiovascular sales were $3.6 billion, a 10.8% jump. Diabetes revenue was $757 million, a 10.3& year over year increase.
5. Medtronic raised its fiscal year 2026 guidance and expects 5.5% full-year growth.
